Sanofi Wins Japan Approval for Sarclisa SC in Myeloma
PARIS | June 19, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the...
Sanofi
Advertisement
Sanofi’s Tzield Gains FDA Approval in Stage 3 Type 1 Diabetes
PARIS, France, June 13, 2026 Sanofi has achieved a major breakthrough in diabetes care after the U.S. Food and...
Sanofi Ends Phase 3 MOBILIZE Trial of Riliprubart in CIDP
PARIS, France, June 10, 2026 Sanofi announced that it will discontinue the Phase 3 MOBILIZE study evaluating riliprubart in...
Sanofi Wins EU Approval for Sarclisa SC in Multiple Myeloma
PARIS, France, June 8, 2026 Sanofi announced that the European Commission has approved Sarclisa® (isatuximab) subcutaneous (SC) for the...
Sanofi’s Venglustat Gains FDA Priority Review for GD3
PARIS, France, May 28, 2026 Sanofi has achieved a major regulatory milestone with the U.S. Food and Drug Administration...
Advertisements
Sanofi’s Efdoralprin Alfa Shows Superior Phase 2 Results in AATD
PARIS, France, May 18, 2026 Sanofi has announced positive Phase 2 ElevAATe trial results demonstrating that investigational therapy efdoralprin...
Sanofi Cenrifki Wins EU CHMP Boost for Progressive MS
PARIS, April 24, 2026 Sanofi has achieved a significant regulatory milestone as the European Medicines Agency’s Committee for Medicinal...
Regeneron & Sanofi Secure FDA Approval for Dupixent in Pediatric CSU
Tarrytown, New York, USA & Paris, France – April 22, 2026 In a significant advancement for pediatric immunology and...
Sanofi Secures FDA Approval for Tzield in Young T1D
Paris, France – April 22, 2026 In a landmark advancement for pediatric endocrinology, Sanofi has secured U.S. FDA approval...
Regeneron Dupixent EU Approval Expands Pediatric CSU Care
TARRYTOWN, N.Y. and PARIS, April 13, 2026 Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved...
Advertisement
